Johnson & Johnson's single-dose COVID-19 vaccine gets emergency use approval in India

New Delhi [India], August 7 : US pharma giant Johnson and Johnson's single-dose COVID-19 vaccine Janssen has received approval for Emergency Use Authorization (EUA) in India, informed Union Health Minister Mansukh Mandaviya on Saturday.
"India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," tweeted the Minister.
Johnson and Johnson on Friday informed it has applied for Emergency Use Authorization (EUA) of its single-dose COVID-19 vaccine Janssen to the Government of India.
The pharma company had stated that it is an important milestone that paves the way to bringing the single-dose COVID-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E. Limited.
The pharma company's statement read, "The EUA submission is based on topline efficacy and safety data from the Phase 3 clinical trial ENSEMBLE, which demonstrated our single-shot vaccine was 85 per cent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination."
India crossed a significant milestone of administering 50 crore vaccine doses under a nationwide vaccination drive.
With 49,55,138 vaccinations in the last 24 hours, India has so far administered a total of 50,10,09,609 doses.